TCGA-A8-A06Z-01A-11R-A00Z-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.450
- OXIDATIVE_PHOSPHORYLATION+0.430
- MYC_TARGETS_V2+0.410
- MTORC1_SIGNALING+0.390
- ADIPOGENESIS+0.340
- E2F_TARGETS+0.300
- DNA_REPAIR+0.290
- MYC_TARGETS_V1+0.290
- UNFOLDED_PROTEIN_RESPONSE+0.270
- G2M_CHECKPOINT+0.260
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.600
- ALLOGRAFT_REJECTION-0.480
- TNFA_SIGNALING_VIA_NFKB-0.470
- INFLAMMATORY_RESPONSE-0.460
- IL6_JAK_STAT3_SIGNALING-0.430
- INTERFERON_GAMMA_RESPONSE-0.430
- IL2_STAT5_SIGNALING-0.350
- KRAS_SIGNALING_UP-0.350
- TGF_BETA_SIGNALING-0.350
- ANGIOGENESIS-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A06Q-01A-11R-A034-07 | — | C | 0.921 |
| 2 | ULC0410T_S45 | — | cohortA4 | 0.915 |
| 3 | SRR10900021 | — | — | 0.910 |
| 4 | BSR_14_0066_A2_S94 | — | C | 0.908 |
| 5 | 5ab068b1-411a-4083-a1ab-3ca7569a54a0 | — | — | 0.901 |
| 6 | f354d13d-89ec-4ed6-821d-df3ab230fc91 | — | — | 0.900 |
| 7 | AUR-AFR3-TTM1-A-1-1-R-A743-41 | — | C | 0.900 |
| 8 | SRR12202421 | — | — | 0.899 |
| 9 | fd49c74b-2a85-46cd-aaa0-dbd2f1284947 | — | — | 0.899 |
| 10 | DRR168601 | — | — | 0.898 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.450 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.430 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.410 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.390 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.340 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.290 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.270 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.260 | Inavolisib | — uncovered |
| PEROXISOME | 0.250 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.240 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.190 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.160 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.150 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.130 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.130 | Cobimetinib | — uncovered |